Jing Ren
Resident in Medicine/Pediatrics at MGH
PGY-3
Pediatric tuberculosis, a multinational approach
I’m working on with the Elizabeth Glaser Pediatric AIDS
Foundation (EGPAF) on a multi-national pediatric tuberculosis project.
Pediatric TB is notorious difficult to diagnose because kids tend to have a
hard time coughing up a sample to test, and the samples tend to have a lower
concentration of TB so our tests are not as sensitive as they are for adults.
One area on which the project focuses is increasing the availability of new child-friendly, fixed-dose formulations
of TB medications. These formulations are easy to take because they dissolve in
water and they reduce the number of pills kids have to take each day, improving
adherence and treatment success. EGPAF is also looking at ways to improve
linkage to/retention in care; not only does this improve patient outcomes but
it also increase the demand for these new pediatric TB medicines, thereby
stabilizing the market and making it worthwhile for more generic drug
manufacturers to make these medicines, which then in turn drives down their
cost.
The proposed
project spans four years and ten countries across sub-Saharan Africa and India.
One of my motivations for doing this rotation with EGPAF is to see how an
organization coordinates this kind of multinational project, as well as see in
action the type of advocacy work organizations are able to do when they are
situated in Geneva in terms of influencing new guidelines that are released. I
had the opportunity to assist with an analysis of the political and current
clinic guidelines for pediatric tuberculosis in each country. This gave me the
opportunity not only to learn about the clinical standard of care in contact
tracing, diagnosis and treatment of TB in children, but also gain more insight
into the nuances in policy that shifted from country to country. After
analyzing multiple national strategic plans and national guidelines, it becomes
easier to differentiate the countries that have the political will and funding
to try to translate strategic goals into concrete action items and guideline
changes.
Being able to
discuss these nuances in public health policy with experts in the field of
pediatric TB and watch them influence the conversations happening on the ground
through our country teams who interact regularly with each National TB Program
was also very interesting. The background of the members of EGPAF Geneva office
range from infectious disease physicians to former Doctors Without Borders
humanitarian aid workers to advocacy experts. I found surprising how few of the
people who work at either the WHO setting these clinical guidelines or in these
large international NGOs that help translate those guidelines into practice
have ever treated a patient with that disease, but I love learning from the
wealth of experience they do have in the field of public health or aid work.